(Q35784263)

10 August 2017

1 reference

title

Current status of live attenuated influenza virus vaccine in the US. (English)

1 reference

10 August 2017

1 reference

1 reference

United States of America

1 reference

1

Robert B Belshe

1 reference

10 August 2017

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

103

1 reference

10 August 2017

issue

1-2

1 reference

10 August 2017

page(s)

177-185

1 reference

Prevention of otitis media in children with live attenuated influenza vaccine given intranasally

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Pilot Studies on Recombinant Cold-Adapted Live Type A and B Influenza Virus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

A mutation in the PA protein gene of cold-adapted B/Ann Arbor/1/66 influenza virus associated with reversion of temperature sensitivity and attenuated virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Single-dose monovalent A 2 -Hong Kong influenza vaccine. Efficacy 14 months after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Virulence of Temperature-sensitive Mutants of Influenza Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Development and characterization of cold-adapted viruses for use as live virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Evaluation of an attenuated, cold-recombinant influenza B virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Determinants of immunity to influenza infection in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Studies in man with cold-recombinant influenza virus (H1N1) live vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Cold-adapted recombinant influenza A virus vaccines in seronegative young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2004.02.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2004.02.031

1 reference

10 August 2017

1 reference